Research programme: anti-CD47 antibodies - Essen BioScience

Drug Profile

Research programme: anti-CD47 antibodies - Essen BioScience

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Essen BioScience
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2017 Preclinical trials in Cancer in USA prior to April 2017 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top